How to diagnose and correct iron deficiency during r-huEPO therapy - A consensus report

Nephrology Dialysis Transplantation

Volumn 11, Issue 2, 1996, Pages 246-250

  Horl W H ^a  

^a UNIVERSITY OF VIENNA   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

FERROUS FUMARATE; FERROUS GLUCONATE; IRON; RECOMBINANT ERYTHROPOIETIN;

CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; HEMODIALYSIS; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; IRON DEFICIENCY; IRON METABOLISM; IRON THERAPY; MAJOR CLINICAL STUDY; META ANALYSIS; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; SHORT SURVEY;

EID: 0030048578     PISSN: 09310509     EISSN: None     Source Type: Journal    
DOI: 10.1093/oxfordjournals.ndt.a027248     Document Type: Short Survey

References (38)

1. Macdougall IC. Poor response to erythropoietin: practical guidelines on investigation and management. Nephrol Dial Transplant 1995; 10: 607-614
2. Macdougall IC. Monitoring of iron status and iron supplementation in patients treated with erythropoietin. Curr Opinion Nephrol Hypertension 1994; 3: 620-625
3. Van Wyck DB, Stivelman JC, Ruiz J, Kirlin LF, Katz MA, Ogden DA. Iron status in patients receiving erythropoietin for dialysis-associated anemia. Kidney Int 1989; 35: 712-716
4. Macdougall IC, Hutton RD, Cavill I, Coles GA, Williams JD. Poor response to treatment of renal anaemia with erythropoietin corrected by iron given intravenously. Br Med J 1989; 299: 157-158
5. Tsobanelis T, Hoppe D, Scigalla P, Grützmacher P. Optimierte Behandlung der renalen Anämie mit kombinierter intravenöser Eisen- und Ultra-low-dose-Erythropoietin-Substitution. NierenHochdruckkrankheiten 1991; 20: 454 (abstract)
6. Eschbach JW, Downing MR, Egrie JC, Browne JK, Adamson JW. USA multicenter clinical trial with recombinant human erythropoietin. Contrib Nephrol 1989; 76: 160-165
7. Anastassiades EG, Howarth D, Howarth J, Shanks D, Waters HM, Hyde K, Geary CG, Yin JAL, Gokal R. Monitoring of iron requirements in renal patients on erythropoietin. Nephrol Dial Transplant 1993; 8: 846-853
8. Nissenson AR, Korbet S, Faber M, Burkart J, Gentile D, Hamburger R, Mattern W, Schreiber M, Swartz R, Van Stone J, Watson A, Zimmerman S. Multicenter trial of erythropoietin in patients on peritoneal dialysis. J Am Soc Nephrol 1995; 5: 1517-1529
9. Faller B, Slingeneyer A, Waller M, Michel C, Grützmacher P, Müller HP, Barany P, Grabensee B, Issad B, Schmitt H, Meisl F. Daily subcutaneous administration of recombinant human erythropoietin in peritoneal dialysis patients: a European dose-response study. Clin Nephrol 1993; 40: 168-175
10. Barany P, Clyne N, Hylander B, Johansson A-C, Simonsen O, Larsson R, Frisenette-Fich C, Svensson B, Helmers C. Subcutaneous epoetin beta in renal anemia: an open multicenter dose titration study of patients on continuous peritoneal dialysis. Perit Dial Int 1995; 15: 54-60
11. Worwood M. Serum Ferritin. In Iron in Biochemistry and Medicine II Academic Press: New York 1980; 203-244
12. Cavill I. Diagnostic Methods. In Disorders of Iron Metabolism. Clin Haematol 1982, II: 259-275
13. Worwood M. Ferritin. Blood Rev 1990; 4: 259-269
14. Macdougall IC, Cavill I, Hulme B, Bain B, McGregor E, McKay P, Sanders E, Coles GA, Williams JD. Detection of functional iron deficiency during erythropoietin treatment: a new approach. Br Med J 1992; 304: 225-226
15. Crosby WH. The rationale for treating iron deficiency. Arch Intern Med 1984; 144: 471-472
16. Wingard RL, Parker RA, Ismail N, Hakim RA. Efficacy of oral iron therapy in patients receiving rhEPO. Am J Kidney Dis 1995; 25: 433-439
17. Schaefer RM, Schaefer L. The hypochromic red cell: a new parameter for monitoring of iron supplementation during rhEPO therapy. J Perinat Med 1995; 23: 83-88
18. Bonnar J, Goldberg A, Smith JA. Do pregnant women take their iron? Lancet 1969; 1: 457-458
19. Dunea G, Swagel MA, Bodiwala U, Arruda JAL. Intradialytic oral iron therapy. Int J Artif Organs 1994; 17: 261-264
20. Heinrich HC. Bioverfügbarkeit und therapeutischer Wert oraler Eisen(II)- und Eisen(III)-Präparate. Deutsch Apothek Zeitschrift 1986; 14: 681-690
21. Magana L, Dahr SK, Smith EC, Martinez C. Iron absorption and utilization in maintenance hemodialysis patients: oral and intravenous routes. Mount Sinai J Med 1984; 51: 180-183
22. Hughes RT, Smith T, Hesp R, Hulme B, Dukes DC, Bending MB, Pearson J, Raja KB, Cotes PM, Pippard MJ. Regulation of iron absorption in iron-loaded subjects with end stage renal disease: effects of treatment with rhEPO and reduction of iron stores. Br J Haematol 1992; 82: 445-454
23. Marchasin S, Wallerstein RO. The treatment of iron-deficiency anemia with intravenous iron dextran. Blood 1961; 23: 354-358
24. Rosenlöf K, Kivivuori SM, Grönhagen-Riska C, Teppo AM, Slimes MA. Iron availability is transiently improved by intravenous iron medication in patients on chronic hemodialysis. Clin Nephrol 1995; 43: 249-55
25. Sunder-Plassmann G, Hörl WH. Importance of iron supply for erythropoietin therapy. Nephrol Dial Transplant 1995; 10: 2070-2076
26. Fishbane S, Lynn RI. The utility for zinc protoporphyrine for predicting the need for intravenous iron therapy in hemodialysis patients. Am J Kidney Dis 1995; 25: 426-32
27. Schaefer RM, Schaefer L. Management of iron substitution during r-HuEPO therapy in chronic renal failure patients. Erythropoiesis 1992; 3: 71-5
28. Nyvad O, Danielsen H, Madsen S. Intravenous iron-sucrose complex to reduce epoietin demand in dialysis patients. Lancet 1994; 344: 1305-6
29. Macdougall IC, Tucker B, Thompson J, Baker LRI, Raine AEG. A randomized controlled study of iron supplementation in patients treated with erythropoietin. J Am Soc Nephrol 1993; 4: 428 (abstract)
30. Sepandj F, Jindal K, West M, Hirsch D. Economic appraisal of maintenance parenteral iron administration in treatment of anemia in chronic hemodialysis patients. Nephrol Dial Transplant 1995 (in press)
31. Hamstra RD, Block MH, Schocket AL. Intravenous iron dextran in clinical medicine. JAMA 1980; 243: 1726-1731
32. Kumpf VJ, Holland EG. Parenteral iron dextran therapy. DICP Ann Pharmacother 1990; 24: 162-166
33. Pascual J, Teruel JL, Llaño F, Sureda A, Ortuno J. Sodium ferric gluconate complex given intravenously for iron-deficiency in haemodialysis. Clin Nephrol 1991; 35: 87 (letter)
34. Ascherio A, Willet WC. Are body iron stores related to the risk of coronary heart disease? N Engl J Med 1994; 330: 1152-1153
35. Sussman HH. Iron in cancer. Pathobiology 1992; 60: 2-9
36. Weinberg ED. Iron withholding: a defense against infection and neoplasia. Physiol Rev 1984; 64: 65-102
37. Macdougall IC. How to get the best out of r-HuEPO. Nephrol Dial Transplant 1995; 10[Suppl. 2]: 85-91
38. Hörl WH, Cavill I, Cove-Smith JR, Eschbach J, Macdougall I, Salmonson T, Schaefer RM, Sunder-Plassmann G. How to get the best out of r-HuEPO. Nephrol Dial Transplant 1995; 10[Suppl. 2]: 92-95